Zynquista
Lexicon Pharmaceuticals Shifts Focus to Clinical Development Following Zynquista Setbacks
Lexicon Pharmaceuticals, Zynquista, FDA, Clinical Development, Restructuring, R&D Pipeline, LX9211, Sotagliflozin, LX9851
FDA Advisory Committee Rejects Lexicon’s Zynquista for Type 1 Diabetes and Chronic Kidney Disease
FDA, Lexicon Pharmaceuticals, Zynquista, sotagliflozin, type 1 diabetes, chronic kidney disease, FDA advisory committee, drug approval
FDA Advisory Committee Votes Against Zynquista for Type 1 Diabetes and Chronic Kidney Disease, Despite Support for Subgroup Benefits
FDA Advisory Committee, Zynquista (sotagliflozin), Type 1 Diabetes (T1D), Chronic Kidney Disease (CKD), Glycemic Control, SGLT1/SGLT2 Inhibitor, Lexicon Pharmaceuticals
Lexicon’s Diabetes Drug Zynquista Faces FDA Scrutiny Again Ahead of Advisory Committee Meeting
Lexicon Pharmaceuticals, Zynquista, FDA, diabetes drug, advisory committee, regulatory challenges
Lexicon Pharmaceuticals Reduces Workforce by 50% to Focus on Diabetes Drug
Lexicon Pharmaceuticals, workforce reduction, diabetes drug, restructuring, Zynquista